SMAD4 and cancer: In sharp contrast, around only 0.3% of the PTEN, SMAD4 or ARID1A mutations in tumours (mean: 0.25–0.39) can be described as passengers in this way (Fig. 2J), suggesting they are true cancer driver genes positively enriched in CRC beyond their level of selection in normal tissue.